Chronic liver diseases Cirrhosis Liver diseases
Conditions
Interventions
Single oral dose of nicotinamide
Sponsors
Hirao Atsushi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Healthy subjects 2) Patients with chronic liver disease 3) Patients with cirrhosis 4) Individuals who have given their free and voluntary written consent to participate in the study after obtaining sufficient informed consent.
Exclusion criteria
Exclusion criteria: 1) Pregnant, lactating, or possibly pregnant 2) Those taking medicines or supplements containing nicotine, nicotinic acid, or NMN. 3) Those with a history of hypersensitivity to medicines containing nicotine, nicotinic acid, or NMN, or to various foods containing nicotine, nicotinic acid, or NMN supplements. 4) Patients with severe hepatic decompensation classified as Child-Pugh Classification B or C 5) Those who are deemed inappropriate as research subjects by the Principal Investigator for other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Bood NAD+ related metabolite levels after taking supplement | — |
Secondary
| Measure | Time frame |
|---|---|
| Urinary NAD+ related metabolite levels after taking supplement | — |
Contacts
Public ContactAtsushi Hirao
Kanazawa University
Outcome results
None listed